Setback for AstraZeneca's much-hyped respiratory portfolio
This article was originally published in Scrip
In a major setback for AstraZeneca's respiratory ambitions, its anti-IL-5 targeting monoclonal antibody failed to meet the primary endpoint in a Phase IIa trial in chronic obstructive pulmonary disease (COPD) as it did not reduce the acute exacerbation rate compared with placebo in the overall population. However Phase III testing of the product, which had already been initiated, is to proceed.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.